Infantile fibrosarcoma (IFS) and congenital mesoblastic nephroma (CMN) are locally aggressive tumors primarily occurring in infants. Both IFS and the cellular subtype of CMN show overlapping morphological features and an ETV6-NTRK3 fusion, suggesting a close relationship. An activating alteration of EGFR, based on an EGFR kinase domain duplication (KDD), occurs in a subset of CMNs lacking an NTRK3 rearrangement, especially in the classic and mixed type. So far no EGFR-KDDs have been detected in IFS. We describe four pediatric tumors at the extremities (leg, n = 2; foot and arm n = 1) with histological features of IFS/CMN. Two cases showed classic IFS morphology while two were similar to classic/mixed type CMN. In all cases, an EGFR-KDD was identified without detection of a fusion gene. There were no abnormalities of the kidneys in any of the patients. This is the first description of IFS with an EGFR-KDD as driver mutation, supporting that IFS and CMN are similar lesions with the same morphological and genetic spectrum. Pathologists should be aware of the more fibrous variant of IFS, similar to classic/mixed type CMN. Molecular analyses are crucial to treat these lesions adequately, especially with regard to the administration of tyrosine kinase inhibitors.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2021.151885DOI Listing

Publication Analysis

Top Keywords

infantile fibrosarcoma
8
egfr kinase
8
kinase domain
8
domain duplication
8
close relationship
8
congenital mesoblastic
8
mesoblastic nephroma
8
classic/mixed type
8
type cmn
8
ifs
7

Similar Publications

Background: Infantile fibrosarcoma (IFS) is a rare pediatric tumor of intermediate malignancy with high local aggressiveness that typically presents in young infants. Its occurrence in the head and neck region is rare. Complete non-mutilating surgical resection is often not possible, requiring multimodal treatment.

View Article and Find Full Text PDF

NTRK (neurotropic tropomyosin receptor kinase)-rearranged spindle cell tumours represent a rare group of molecularly defined soft tissue neoplasms. These tumours, excluding infantile fibrosarcomas, are characterised by NTRK gene rearrangements and exhibit a range of histomorphologies, including spindle, epithelioid or rhabdoid cells with invasive growth. Their prognosis correlates with histological grade, and surgical resection is the primary treatment.

View Article and Find Full Text PDF

Purpose: The TRK inhibitor larotrectinib is US Food and Drug Administration approved for fusion-positive solid tumors that lack a satisfactory alternative or have progressed after treatment but has not been systematically studied as a frontline therapy with a defined duration of treatment. ADVL1823 evaluated larotrectinib in patients with newly diagnosed fusion-positive solid tumors with response-adapted duration of therapy and local control.

Methods: Patients received larotrectinib twice daily in 28-day cycles for a predefined duration of treatment, ranging from 6 to 26 cycles depending on response to therapy and surgical resectability.

View Article and Find Full Text PDF
Article Synopsis
  • - Congenital peribronchial myofibroblastic tumor (CPMT) is a rare benign tumor found in infants, identified by unique histological features, including cartilaginous islands and spindle cells, which can lead to serious complications despite its benign classification.
  • - Genetic analysis reveals that a specific alteration, the EGFR kinase domain duplication (KDD), is a common oncogenic driver in CPMT cases, suggesting that CPMT and similar tumors, like congenital mesoblastic nephromas, may share underlying molecular mechanisms and be related.
  • - Following surgical resection of the tumors, patients demonstrated varied outcomes; while one patient died shortly after surgery, the remaining three were free of recurrence, indicating
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!